SCHEMBL729384

SCHEMBL729384

COC(=O)c1ccc(OC)c(OCC2CC2)c1NC(C)=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 4/20 0.47
TDP1 Q9NUW8 1/20 0.41
HTR1A P08908 1/20 0.41
HTR2A P28223 1/20 0.41
HTR7 P34969 1/20 0.41
HTR6 P50406 1/20 0.41
PARP15 Q460N3 1/20 0.40
PARP10 Q53GL7 1/20 0.40
PDE4B Q07343 6/20 0.39
PDE4A P27815 3/20 0.39
PDE4C Q08493 3/20 0.39
KDM4E B2RXH2 3/20 0.39
HSD17B10 Q99714 3/20 0.39
USP2 O75604 1/20 0.39
POLB P06746 1/20 0.39
ALDH1A1 P00352 3/20 0.38
MAPT P10636 1/20 0.38
TSHR P16473 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL729280 0.81 PDE4D (0.49) PDE4DPARP15PARP10PDE4BPDE4A
SCHEMBL731158 0.79 PDE5A (0.48) PDE4DPDE4BPDE4APDE4CPOLB
SCHEMBL730471 0.77 PDE4D (0.46) PDE4DTDP1PARP15PARP10PDE4B
SCHEMBL6771073 0.73 ALDH1A1 (0.45) PARP15PARP10PDE4BKDM4EHSD17B10
SCHEMBL6768887 0.73 ALDH1A1 (0.48) PARP15PARP10KDM4EHSD17B10POLB
SCHEMBL3225627 0.73 PARP10 (0.67) PDE4DTDP1PARP15PARP10PDE4B
SCHEMBL6769221 0.72 ALDH1A1 (0.50) PARP15PARP10KDM4EHSD17B10POLB
SCHEMBL2847850 0.71 PDE4B (0.43) PDE4DTDP1PARP15PARP10PDE4B
SCHEMBL4278555 0.69 PDE4B (0.63) PDE4DPDE4BPDE4APDE4CMAPT
SCHEMBL2090601 0.69 PDE4B (0.60) PDE4DPDE4BPDE4APDE4CMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130045975-A1 BICYCLIC HETEROARYL INHIBITORS OF PDE4 KALYPSYS, INC. (US) 2013-02-21 US disclosed
EP-2467376-A1 BICYCLIC HETEROARYL INHIBITORS OF PDE4 Kalypsys, Inc. (US) 2012-06-27 EP disclosed
US-8138205-B2 Heteroarylalkoxy-substituted quinolone inhibitors of PDE4 KALYPSYS, INC. (US) 2012-03-20 US disclosed
WO-2011093924-A1 BICYCLIC HETEROARYL INHIBITORS OF PDE4 KALYPSYS, INC (US) 2011-08-04 WO disclosed
US-20100081646-A1 BICYCLIC HETEROARYL INHIBITORS OF PDE4 KALYPSYS, INC. (US) 2010-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130045975-A1 BICYCLIC HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C PDE4D 9/4885TDP1 344/4885HTR1A 2803/4885
US-20100081646-A1 BICYCLIC HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C PDE4D 9/4885TDP1 344/4885HTR1A 2803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.